| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702684 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
Only 51% of urologic oncologists report using pIVC in patients undergoing RNU. Reasons underlying this underutilization are multifactorial, thereby underscoring the need for continued dissemination of existing data and additional studies to support its benefits. Moreover, improving the logistics of pIVC administration may help to increase utilization rates.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Diane D. M.D., Stephen A. M.D., Jay D. M.D.,